In this article, we will look at the 10 Fastest Growing Tech Penny Stocks to Buy.
Tech penny stocks sit at the speculative end of the market, but they are getting more attention as investors look below mega-cap software and semiconductor names for faster revenue growth. The group can include AI infrastructure suppliers, digital platforms, electronics, communications equipment, and biotechnology companies whose value is driven by proprietary scientific platforms rather than conventional healthcare delivery.
Royce Investment Partners says “micro-cap stocks are leading the market” and notes that its investable universe includes “many companies selling into the AI supply chain,” including firms providing the “picks and shovels for the AI revolution.” Fidelity also supports the broader technology spending backdrop, saying it sees “no prospect of flagging AI spending” and expects “graphics processing units, high-speed memory and data centers” to remain important in 2026 and beyond. It also points to other technology themes such as “cloud computing, digital transformation, and digital security.” For the biotech names in a broad tech screen, Janus Henderson gives the clearest bridge, saying biotechnology sits at the frontier of “therapeutics innovation,” where “AI, genomics, and molecular engineering” are “accelerating the pace of discovery.”
Against this backdrop, fast-growing tech penny stocks are not just about low-priced speculation. Some companies are tied to real technology platforms, applied science, and infrastructure demand. With that in mind, let’s take a look at the 10 Fastest Growing Tech Penny Stocks to Buy.
Our Methodology
We used the Finviz screener to identify tech stocks that are trading below $5 per share and have posted compounded annual revenue growth of over 50% in the past 3 years. We then limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Note: Some companies below are not pure-play tech stocks. Even so, they maintain a notable presence in the technology space through various aspects of their business.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter strategy selects 14 small-cap and large-cap stocks every quarter and has returned 599.2% since May 2014, beating its benchmark by 372 percentage points (see more details here).
10. PowerFleet, Inc. (NASDAQ:AIOT)
On July 1, 2026, PowerFleet, Inc. (NASDAQ:AIOT) announced the Australian launch of SafeGuard, an AI-powered risk intelligence solution for on-road driver behavior. Available as an add-on to Powerfleet’s VisionAI video solution and integrated within the Unity platform, SafeGuard uses artificial intelligence to assess driver risk across a fleet and help safety teams focus on events and behaviors most likely to lead to incidents. Brodie von Berg, Managing Director, Powerfleet APAC, said SafeGuard helps teams identify the “highest-risk drivers and behaviours” in real time, supporting earlier intervention and coaching.
Powerfleet said SafeGuard combines real-time risk monitoring, AI-powered driving risk analysis, intelligent video event review, and live intervention capabilities. Operators using SafeGuard have reported up to 83% reduction in on-road risk, 95% fewer false positive video event alerts, and an 80% reduction in video review time.
Also on July 1, PowerFleet announced that its Board of Directors approved a stock repurchase program authorizing the company to repurchase up to $30M of common stock over the next 24 months. On June 16, Raymond James lowered the firm’s price target on PowerFleet to $7 from $8 and kept an Outperform rating on the shares. Raymond James said Q4 results came in ahead of expectations, with an improved FY27 outlook reflecting accelerating growth and profitability into year-end.
PowerFleet, Inc. (NASDAQ:AIOT) provides artificial intelligence-of-things solutions for managing high-value enterprise and mid-market assets in North America, Israel, Africa, Europe, the Middle East, Australia, and internationally.
9. Geron Corporation (NASDAQ:GERN)
On June 18, 2026, Geron Corporation (NASDAQ:GERN) reported that, effective June 17, 2026, it granted stock options to purchase an aggregate of 690,000 shares of common stock to eight newly hired employees. The grants were made as an inducement material to the employees’ acceptance of employment with Geron.
The stock options have an exercise price of $1.23 per share, equal to the closing price of Geron’s common stock on the grant date. The options have a ten-year term and vest over four years, with 12.5% of the shares underlying the options vesting on the six-month anniversary of the employee’s employment commencement and the remaining shares vesting over the following 42 months in equal installments, subject to continued employment.
Earlier in June, Geron Corporation (NASDAQ:GERN) announced that members of its management team were scheduled to participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference.
Geron Corporation (NASDAQ:GERN) focuses on the development of therapeutic products for oncology.
8. Nano Dimension Ltd. (NASDAQ:NNDM)
On June 16, 2026, Nano Dimension Ltd. (NASDAQ:NNDM) and Infinite Epigenetics issued a shareholder update on the proposed business combination announced on June 15. Nano said it reviewed Murchinson’s recent letter on the proposed transaction and noted that final transaction details were still being negotiated. The company said it would provide complete details and a description of the proposed transaction once finalized.
Nano said Infinite Epigenetics is “not a concept company” and “not an AI wrapper,” pointing to operating businesses, a CLIA-certified methylation laboratory, existing commercial revenue, a network of more than 7,500 healthcare providers, issued intellectual property, and a proprietary database of more than 120,000 biological samples. The company also said Infinite’s team has authored over 50 publications, and that a single sample processed in Infinite’s CLIA-certified laboratory can read more than one million epigenetic signals. Nano said it selected Infinite from approximately 20 opportunities it evaluated and framed the transaction as a shift from 3D printing to AI-powered preventive health and diagnostics.
Nano said the term sheet with Infinite followed a months-long review process with support from financial and legal advisors, as well as consultants assessing Infinite’s technology, target markets, and operations. The company said the proposed combination values Nano at net cash plus a 20% premium, preserves the value of Nano’s Nasdaq listing, allows holders to retain contingent value rights on Nano’s legacy assets, and adds equity upside. Nano also said the contemplated transaction would not provide separate or transaction-driven compensation or payouts and that any definitive agreement would be subject to a shareholder vote.
Nano Dimension Ltd. (NASDAQ:NNDM) provides industrial manufacturing solutions for design-to-manufacturing of electronics and mechanical parts in the Americas, the Asia Pacific, Europe, the Middle East, and Africa.
7. Century Therapeutics, Inc. (NASDAQ:IPSC)
On July 9, 2026, Century Therapeutics, Inc. (NASDAQ:IPSC) announced that its abstracts were accepted for oral presentations at two upcoming scientific congresses. Both presentations will highlight CNTY-813, Century’s iPSC-derived islet replacement therapy program engineered with Allo-Evasion™ 5.0 for patients with type 1 diabetes.
The presentations are scheduled for the 62nd Annual Meeting of the European Association for the Study of Diabetes, taking place September 28-October 2, 2026 in Milan, Italy, and the Breakthrough T1D Clinical & Research Congress 2026, taking place October 9-11, 2026 in Philadelphia, Pennsylvania. Century said CNTY-813 is designed to enable durable engraftment without chronic systemic immunosuppression, and the company is targeting an IND submission in the fourth quarter of 2026.
On June 9, Century Therapeutics announced new preclinical data for CNTY-813 at the American Diabetes Association Scientific Sessions. In preclinical models, the therapy demonstrated durable glucose control for over eight months and maintained insulin secretion under allogeneic immune pressure without immunosuppression. CEO Brent Pfeiffenberger said the data advance the company’s case for a “potentially functional cure” for type 1 diabetes, while noting that the IND submission remains on track for the fourth quarter of 2026 and initial clinical data are anticipated in the second half of 2027.
Century Therapeutics, Inc. (NASDAQ:IPSC) develops allogeneic cell therapies for the treatment of solid tumors, hematological malignancies, and autoimmune diseases.
6. TON Strategy Co (NASDAQ:TONX)
On July 1, 2026, TON Strategy Co (NASDAQ:TONX) announced that it entered into a Rule 10b5-1 trading plan to facilitate the repurchase of common stock during a two-month period beginning July 1. The plan was established under the company’s existing $250M stock repurchase authorization announced on September 3, 2025. Virtu Financial will serve as the executing broker under the plan.
On June 15, TON Strategy highlighted the TON community’s rebrand of Toncoin, the native currency of The Open Network, to “Gram.” The rebrand followed a community governance vote that concluded on June 8, 2026, with public reports indicating that 81.22% of participating voting power supported the proposal. TON Strategy said the rebrand changes the native asset ticker, while the underlying blockchain and network name remain TON. No token swap, migration, bridge, claim, or conversion is required, and TON Strategy’s Nasdaq ticker, TONX, is unchanged.
CEO Kevin Wilson called the move from Toncoin to Gram an “important identity milestone” for the TON ecosystem, saying the new name can help make the network easier for users to understand as TON develops around Telegram-native use cases. The company also said recent TON ecosystem developments have focused on improving usability, performance, and developer experience.
TON Strategy Co (NASDAQ:TONX) operates as an interactive video-based social commerce company.
While we acknowledge the potential of TONX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than TONX and that has 100x upside potential, check out our report about the cheapest AI stock.
Click to continue reading and see the 5 Fastest Growing Tech Penny Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.
